Adverse Events During Perampanel Adjunctive Therapy in Intractable Epilepsy

BACKGROUND AND PURPOSE: Perampanel is the first α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA)-receptor antagonist developed to treat epilepsy. The effects of either rapid or slow dose titration on adverse events remain to be elucidated. METHODS: Eighty-five patients received perampane...

Descripción completa

Detalles Bibliográficos
Autores principales: Youn, Song Ee, Kim, Se Hee, Ko, Ara, Lee, Sun Ho, Lee, Young Mock, Kang, Hoon-Chul, Lee, Joon Soo, Kim, Heung Dong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Korean Neurological Association 2018
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031997/
https://www.ncbi.nlm.nih.gov/pubmed/29971974
http://dx.doi.org/10.3988/jcn.2018.14.3.296

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6031997/
https://www.ncbi.nlm.nih.gov/pubmed/29971974
http://dx.doi.org/10.3988/jcn.2018.14.3.296

Ejemplares similares